Left-Right Comparison Study of the Combination of Fluticasone Propionate and UV-A vs Either Fluticasone Propionate or UV-A Alone for the Long-term Treatment of Vitiligo
Open Access
- 1 September 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 135 (9), 1061-1066
- https://doi.org/10.1001/archderm.135.9.1061
Abstract
VITILIGO IS an acquired pigmentary skin disorder, often with a progressive course. Much about the cause of vitiligo remains uncertain. It is possible that autoimmune mechanisms are involved in its pathogenesis, as an increased incidence of autoantibodies has been found in patients with vitiligo.1,2 Furthermore, vitiligo is often associated with autoimmune diseases such as thyroid diseases and diabetes mellitus. Another indication that vitiligo may be an autoimmune disease is the fact that antibodies to melanocyte-associated antigens have been found in patients with vitiligo and correlate with disease activity.3,4 Involvement of cellular immunity has been considered because T lymphocytes and macrophages in perilesional skin have been reported frequently.5,6Keywords
This publication has 7 references indexed in Scilit:
- Glucocorticoid Stimulates Melanogenesis and Tyrosinase Gene Expression in B16 Melanoma CellsPigment Cell Research, 1991
- Detection of Antibodies to Melanocytes in Vitiligo by Specific ImmunoprecipitationJournal of Investigative Dermatology, 1983
- Association of HLA-DR4 with vitiligoJournal of the American Academy of Dermatology, 1983
- Observations on the systemic effect of topical clobetasol propionate (Dermovate).BMJ, 1975
- Treatment of Vitiligo by Local Application of Betamethasone 17-Valerate in a Dimethyl Sulfoxide Cream BaseDermatology, 1973
- Dendritic cell dynamics in progressive depigmentationsArchiv für dermatologische Forschung, 1972
- Vitiligo – Response to 0.2 % Betamethasone 17-Valerate in Flexible CollodionDermatology, 1970